Clinical trial NCT01194206: Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
Official title: Downstaging of Hepatocellular Carcinoma by Stereotactic Body Radiotherapy for Non-Resectable and Non-Transplantable Tumors: Phase 2 Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2010-09-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue in patients with liver cancer. Giving stereotactic body radiation therapy may also increase patient eligibility for liver transplant.PURPOSE: This phase II trial is studying how well stereotactic body radiation therapy works in treating patients with liver cancer that cannot be removed by surgery or transplant.

Detailed description: PRIMARY OBJECTIVES:I. To determine in patients with stage B and C Hepatocellular Carcinoma, if Stereotactic Body Radiotherapy can achieve a downstaging rate of \>= 30% at 3 months.SECONDARY OBJECTIVES:I. To determine in patients with stage B and C Hepatocellular Carcinoma, if Stereotactic Body Radiotherapy can achieve a downstaging rate of \>= 30% at 3 and 6 months.II. To determine the rate of Grade 3 or 4 adverse events associated with SBRT for liver tumors. III. To determine the rate of local progression after SBRT. (Based onRECIST criteria)IV. To determine the number of patients who achieve liver transplantation.OUTLINE:Patients undergo 3 fractions of stereotactic body radiation therapy delivered within 14 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for 2 years.

Eligibility criteria: Inclusion Criteria:

* HCC is staged as Barcelona B or C (non-resectable and non-transplantable)
* Treatment with SBRT can occur within 6 weeks of staging laparoscopy
* Patient has a) Radiographic enhancing liver lesions on triple phase CT or MRI and b) Histological confirmation of HCC
* Patients with clinical/imaging features of HCC but without biopsy confirmation can be initially enrolled on the protocol and undergo staging laparoscopy for biopsy confirmation with the option of having the fiducials placed in the same procedure; but if the histology is not confirmed and/or other exclusion criteria is met patient will be taken off protocol
* Total aggregate of maximal dimension of liver tumors =\< 8 cm
* Cirrhotic patients Child Pugh Class A or B
* Patient should be medically eligible for liver transplantation
* Absolute neutrophil count \> 1,500/ul
* Platelets \> 50,000 ul (after transfusion if required)
* Hemoglobin greater than 10.0 g/dL
* Total bilirubin \< 2.0 mg/dL
* AST(SGOT)/ALT(SGPT) \< 2 X institutional upper limit of normal
* Life expectancy \> 12 weeks
* ECOG performance status \< 2 or Karnofsky \>= 70%
* Women of child-bearing potential must have a negative pregnancy test within 4 weeks to the start of the SBRT treatment
* Women must not be pregnant or nursing
* Sexually active men and women must agree to use accepted forms of birth control
* Provision of informed consent: Patient must be able to provide verbal and written informed consent

Exclusion Criteria:

* Patient with previous history of abdominal radiation
* Prior invasive malignancy other than primary liver malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
* Evidence of metastatic disease prior to staging laparoscopy
* Evidence of main Portal Vein thrombosis
* History of cardiac ischemia or stroke within last 6 months
* Any concurrent medical or psychosocial condition that prohibits a major surgical procedure or immunosuppression that would constitute a contraindication to liver transplantation

Primary outcomes:
measure: Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy
timeFrame: At 3 months
Secondary outcomes:
measure: Rate of Grade 3 or 4 adverse events associated with SBRT for liver tumors as assessed by NCI CTCAE version 4.0
timeFrame: Baseline, at 1 month, 3 months and 6 months
measure: Rate of local progression as assessed by RECIST criteria
timeFrame: Baseline, at 1 month, 3 months and 6 months
measure: Number of patients who achieve liver transplantation
timeFrame: at 6 months after SBRT
measure: Survival rate
timeFrame: Survival will be measured from the first day of treatment on study until death of any cause.
Other outcomes:
Locations:
Study officials:
affiliation: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
name: Juan Sanabria
role: PRINCIPAL_INVESTIGATOR
References: